Lexeo Therapeutics, Inc. (LXEO) vs Palisade Bio, Inc. (PALI)

Lexeo Therapeutics, Inc. and Palisade Bio, Inc. are both Biotechnology companies. Lexeo Therapeutics, Inc. and Palisade Bio, Inc. are of similar size ($278.3M and $273.6M). Lexeo Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 2.2×. Lexeo Therapeutics, Inc. has the higher net margin (0.00% vs −4,230.6%) and the lower return on invested capital (−253.5% vs 0.00%). Across the 14 metrics below, Lexeo Therapeutics, Inc. leads on 7 and Palisade Bio, Inc. on 7.

Valuation

Metric LXEO PALI Biotechnology median
P/E n/m 2.24 7.88
P/S n/m 405.97 11.47
P/B 1.21 2.52 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 240.84 10.73
Earnings yield (34.74%) 44.66% (28.84%)
Free cash flow yield (31.30%) (5.94%) (23.03%)

Profitability

Metric LXEO PALI Biotechnology median
Gross margin 0.00% 95.63% 65.16%
Operating margin 0.00% (4,681.99%) 0.00%
Net margin 0.00% (4,230.60%) 0.00%
Free cash flow margin 0.00% (2,409.27%) 0.00%
Return on equity (46.76%) (51.37%) (57.72%)
Return on assets (40.50%) (47.68%) (49.22%)
Return on invested capital (253.48%) 0.00% 0.00%

Growth

Metric LXEO PALI Biotechnology median
Revenue growth (TTM) — 5,492.59% 5.64%
EPS growth (last fiscal year) 39.81% 97.06% —
Revenue growth, 5-year CAGR — 72.86% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LXEO PALI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 13.89 24.26 4.73
Net debt to EBITDA 1.67 7.37 0.96

Dividend

Metric LXEO PALI Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric LXEO PALI Biotechnology median
Market cap 278.28m 273.60m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack